Medical, but hold the marijuana: new CBD source found in Brazil

Medical, but hold the marijuana: new CBD source found in Brazil

Brazilian molecular biologist Rodrigo Moura Neto inspects a plant that contains CBD, which can be used to treat epilepsy and crhonic pain, at his laboratory at the Federal University of Rio de Janeiro in June 2023
Brazilian molecular biologist Rodrigo Moura Neto inspects a plant that contains CBD, which can be used to treat epilepsy and crhonic pain, at his laboratory at the Federal University of Rio de Janeiro in June 2023. Photo: CARL DE SOUZA / AFP
Source: AFP

PAY ATTENTION: Never miss breaking news – join Briefly News' Telegram channel!

In a laboratory tucked away on a sprawling university campus in Rio de Janeiro, Brazilian molecular biologist Rodrigo Moura Neto is running tests on a seemingly ordinary plant with a potent secret.

The fast-growing, homely plant, Trema micrantha blume, is native to the Americas, where it is widespread and often considered a weed.

But Moura Neto recently discovered its fruits and flowers contain one of the active ingredients in marijuana: cannabidiol, or CBD, which has shown promise as a treatment for conditions including epilepsy, autism, anxiety and chronic pain.

Crucially, he also found it does not contain the other main ingredient in pot, tetrahydrocannabinol, or THC -- the psychoactive substance that makes people high.

That opens the possibility of an abundant new source of CBD, without the complications of cannabis, which remains illegal in many places.

Read also

Nestle steps up reforestation project in Ivory Coast

The discovery has made something of an overnight academic star of Dr Moura Neto, an affable, silver-haired 66-year-old who now has a packed schedule of meetings with patent experts and companies keen to tap the multi-billion-dollar CBD market.

PAY ATTENTION: Click “See First” under the “Following” tab to see Briefly News on your News Feed!

"It was wonderful to find a plant (with CBD but) without THC, because you avoid all the mess around psychotropic substances," says Moura Neto, who has spent the better part of five decades researching in this small lab at Rio de Janeiro Federal University.

"That means the potential is enormous," he tells AFP.

His 10-member team recently won a 500,000-real ($104,000) public grant to expand his project, which will now identify the best methods to extract CBD from "Trema," then study its effectiveness as a substitute for medical marijuana.

Man in demand

Read also

Culture wars put American companies on the defensive

View of the Trema micrantha blume plant, a fast-growing plant that is native to the Americas where it is widespread and often considered a weed
View of the Trema micrantha blume plant, a fast-growing plant that is native to the Americas where it is widespread and often considered a weed. Photo: CARL DE SOUZA / AFP
Source: AFP

Many of CBD's touted medical uses are still under research.

The compound is controversial, including in Brazil, where patients have gone to court to win the right to use it. They often have to import it at eye-watering prices, given that cultivating medical marijuana remains illegal -- though there is legislation before Congress to change that.

Debates aside, demand for CBD is booming.

The global market for CBD last year was estimated at nearly $5 billion. Analytics firm Vantage Market Research projects it will grow to more than $47 billion by 2028, driven mainly by health and wellness use.

Interest in Moura Neto's research has been "huge," says Rosane Silva, the director of his laboratory, which sits off a hallway bustling with students and researchers in white lab coats.

"Lots of companies have been calling, looking to collaborate" on an eventual non-cannabis-based CBD medication, Silva says, standing beside what she calls the "magical plant."

Read also

As prices soar, Japan returns to human waste fertiliser

A member of the Cannabaceae family -- like cannabis -- "Trema" can grow into a tree up to 20 meters (66 feet) tall.

Moura Neto says he and the university may explore patenting any innovations they find for extracting CBD from its tiny fruits and flowers.

But he is quick to add he won't patent "Trema" itself. He wants scientists everywhere to be able to research it.

"If I dreamed of being a billionaire, I wouldn't have become a professor," he says.

From policing to producing?

Moura Neto started studying CBD for a completely different reason: trained as a forensic geneticist, he would analyze the DNA of marijuana seized by police to help investigators trace its source.

When he came across a study that identified CBD in a related plant in Thailand -- another member of the Cannabaceae family -- he got the idea to test for it in "Trema."

Read also

Israel enlists drones, AI and big data to farm for the future

He says turning his still-unpublished findings into a drug ready for market will take five to 10 years of research and clinical trials -- if it is possible at all.

Trema micrantha blume contain one of the ingredients in marijuana, CBD, which shows promise treating  epilepsy, autism, anxiety and chronic pain, but not the other main ingredient  THC that makes people high
Trema micrantha blume contain one of the ingredients in marijuana, CBD, which shows promise treating epilepsy, autism, anxiety and chronic pain, but not the other main ingredient THC that makes people high. Photo: CARL DE SOUZA / AFP
Source: AFP

Cannabis, first domesticated in China more than 10,000 years ago, has been cultivated for millennia to hone its mind-altering and medicinal effects.

CBD from "Trema" might not work as well, or at all, Moura Neto says.

In the meantime, it's no use smoking the plant for a high.

"That definitely won't do anything for you," he laughs.

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ click on “Recommended for you” and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.